Ken Yu Lin
Radical cancer surgery and minimally invasive surgery using laparoscopy and the da Vinci robotic platform
The long-term objective of Dr. Lin’s research is to develop immunotherapy and biomarker-driven targeted therapy for gynecologic cancers.
<p>Ken Yu Lin, MD, is an Associate Professor, Obstetrics & Gynecology and Women’s Health at Montefiore Einstein. He provides comprehensive, compassionate evidence-based care for women with gynecologic cancers. Dr. Lin performs radical cancer surgery and minimally invasive surgery using laparoscopy and the da Vinci robotic platform.</p><p>After obtaining his Bachelor of Science in chemistry from Stanford University in 1997, Dr. Lin earned his Doctor of Philosophy in biochemistry and cell and molecular biology at Johns Hopkins University in 2006, where he performed research in tumor immunology. He received his Doctor of Medicine at Northwestern University in 2007 before completing an obstetrics & gynecology residency at Yale-New Haven Hospital in 2011. He then completed his gynecologic oncology fellowship at the University of Texas Southwestern Medical Center in 2015.</p><p>The long-term objective of Dr. Lin’s research is to develop immunotherapy and biomarker-driven targeted therapy for gynecologic cancers. Through his collaborations with biomedical scientists and participation in NRG Oncology, Dr. Lin’s research spans several areas. These include developing immunotherapy for ovarian cancer, the biology of uterine serous carcinoma and developing therapy for gynecologic cancers of less common histology, particularly ovarian clear cell carcinoma and carcinosarcoma. His work has been published in numerous peer-reviewed journals, books, chapters, articles and abstracts, including <em>Cancer Research</em>, <em>Cell</em>, and <em>Science Translational Medicine</em>.</p><p>Dr. Lin is board certified in Obstetrics & Gynecology and Gynecologic Oncology and is a member of the Society of Gynecologic Oncology. He participated in the Reproductive Scientist Development Program (RSDP) from 2015 to 2018 and won the Gynecological Oncology Group (GOG) Foundation Early Investigator Award in 2019. He serves on the NRG Oncology Rare Tumor Committee.</p>